Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

(2020) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities

(2020) Dane Cheasley et al.   JOURNAL OF PATHOLOGY

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

(2019) Monica Tang et al.   GYNECOLOGIC ONCOLOGY

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

(2019) Martin Gore et al.   GYNECOLOGIC ONCOLOGY

Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics

(2018) Jaime Prat et al.   HUMAN PATHOLOGY

Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience

(2017) Heather J. Dalton et al.   GYNECOLOGIC ONCOLOGY

Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?

(2017) Amanda N. Fader et al.   GYNECOLOGIC ONCOLOGY

Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum

(2017) David M. Gershenson et al.   JOURNAL OF CLINICAL ONCOLOGY

Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

(2016) Jacek P. Grabowski et al.   GYNECOLOGIC ONCOLOGY

Genetic and molecular changes in ovarian cancer

(2016) Robert L Hollis et al.   Cancer Biology & Medicine

Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum

(2015) David M Gershenson et al.   BRITISH JOURNAL OF CANCER

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer

(2015) K. E. Hew et al.   CLINICAL CANCER RESEARCH

Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor

(2015) David M. Gershenson et al.   JOURNAL OF CLINICAL ONCOLOGY

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver

(2014) C. Emmanuel et al.   CLINICAL CANCER RESEARCH

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

(2012) David M. Gershenson et al.   GYNECOLOGIC ONCOLOGY

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

Reclassification of serous ovarian carcinoma by a 2-tier system

(2011) Diane C. Bodurka et al.   CANCER

Low-grade serous carcinomas of the ovary contain very few point mutations

(2011) Siân Jones et al.   JOURNAL OF PATHOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas

(2010) Kwong-Kwok Wong et al.   AMERICAN JOURNAL OF PATHOLOGY

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

(2009) David M. Gershenson et al.   GYNECOLOGIC ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER